Suchergebnisse - "Antipsychotic Agents/therapeutic use"

Efficacy of clozapine versus second-generation antipsychotics in people with treatment-resistant schizophrenia: a systematic review and individual patient data meta-analysis

Autoren: Schneider-Thoma, Johannes Hamza, Tasnim Chalkou, Konstantina et al.

Quelle: The lancet / Psychiatry 12(4), 254-265 (2025). doi:10.1016/S2215-0366(25)00001-X
The lancet. Psychiatry, vol. 12, no. 4, pp. 254-265

Schlagwörter: therapeutic use [Clozapine], Adult, Male, drug therapy [Schizophrenia, Treatment-Resistant], Treatment Outcome, therapeutic use [Antipsychotic Agents], Humans, Clozapine/therapeutic use, Antipsychotic Agents/therapeutic use, Schizophrenia, Treatment-Resistant/drug therapy, Randomized Controlled Trials as Topic, Schizophrenia/drug therapy, Female, Schizophrenia, ddc:610, Clozapine, Schizophrenia, Treatment-Resistant, Antipsychotic Agents

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/40023172
https://serval.unil.ch/notice/serval:BIB_73C89CC308BB
https://serval.unil.ch/resource/serval:BIB_73C89CC308BB.P001/REF.pdf
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_73C89CC308BB7

Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis: a systematic review and meta-analysis

Autoren: Højlund, Mikkel Köhler-Forsberg, Ole Gregersen, Anton T. et al.

Quelle: Højlund, M, Köhler-Forsberg, O, Gregersen, A T, Rohde, C, Mellentin, A I, Anhøj, S J, Kemp, A F, Fuglsang, N B, Wiuff, A C, Nissen, L, Sørensen, M A, Madsen, N M, Wagner, C B, Agharazi, A, Søndergaard, C, Sandmark, M, Reinhart, J & Correll, C U 2024, 'Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy : a systematic review and meta-analysis', The Lancet Psychiatry, vol. 11, no. 12, pp. 975-989. https://doi.org/10.1016/S2215-0366(24)00314-6

Schlagwörter: Mental Disorders, Polypharmacy, Prevalence, Humans, Mental Disorders/drug therapy, Antipsychotic Agents/therapeutic use, Antipsychotic Agents

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39547246
https://portal.findresearcher.sdu.dk/da/publications/8e9ad8ec-fc71-4a9b-b667-84bf69884dcf
https://doi.org/10.1016/S2215-0366(24)00314-6

Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study

Autoren: Camporesi, Sara Xin, Lijing Golay, Philippe et al.

Quelle: Mol Psychiatry
Molecular psychiatry, vol. 29, no. 11, pp. 3669-3679
Camporesi, Sara; Xin, Lijing; Golay, Philippe; Eap, Chin Bin; Cleusix, Martine; Cuenod, Michel; Fournier, Margot; Hashimoto, Kenji; Jenni, Raoul; Ramain, Julie; Restellini, Romeo; Solida, Alessandra; Conus, Philippe; Do, Kim Q; Khadimallah, Ines (2024). Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. (In Press). Molecular psychiatry Springer Nature 10.1038/s41380-024-02631-4 <http://dx.doi.org/10.1038/s41380-024-02631-4>
Camporesi, Sara; Xin, Lijing; Golay, Philippe; Eap, Chin Bin; Cleusix, Martine; Cuenod, Michel; Fournier, Margot; Hashimoto, Kenji; Jenni, Raoul; Ramain, Julie; Restellini, Romeo; Solida, Alessandra; Conus, Philippe; Do, Kim Q; Khadimallah, Ines (2024). Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. Molecular psychiatry, 29(11), pp. 3669-3679. Springer Nature 10.1038/s41380-024-02631-4 <http://dx.doi.org/10.1038/s41380-024-02631-4>

Schlagwörter: Male, Adult, Adolescent, Psychotic Disorders / metabolism, Glutamic Acid, 610 Medicine & health, Schizophrenia, Treatment-Resistant / metabolism, Glutamic Acid / metabolism, Neuropsychological Tests, Humans, Female, Longitudinal Studies, Psychotic Disorders/drug therapy, Psychotic Disorders/metabolism, Receptors, N-Methyl-D-Aspartate/metabolism, Young Adult, Follow-Up Studies, Cognitive Dysfunction/drug therapy, Cognitive Dysfunction/metabolism, Antipsychotic Agents/therapeutic use, Antipsychotic Agents/pharmacology, Case-Control Studies, Cognition/physiology, Cognition/drug effects, Schizophrenia, Treatment-Resistant/drug therapy, Schizophrenia, Treatment-Resistant/metabolism, Glutamic Acid/metabolism, Schizophrenia/drug therapy, Schizophrenia/metabolism, Brain/metabolism, Receptors, N-Methyl-D-Aspartate, Receptors, N-Methyl-D-Aspartate / metabolism, Article, Cognition, Psychotic Disorders / drug therapy, Cognitive Dysfunction, Cognition / physiology, Cognitive Dysfunction / drug therapy, Schizophrenia / metabolism, Antipsychotic Agents / pharmacology, Schizophrenia, Treatment-Resistant / drug therapy, Schizophrenia / drug therapy, Brain, Cognitive Dysfunction / metabolism, Psychotic Disorders, Cognition / drug effects, 616.89, Schizophrenia, Brain / metabolism, Antipsychotic Agents / therapeutic use, Schizophrenia, Treatment-Resistant, Antipsychotic Agents

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38849515
https://archive-ouverte.unige.ch/unige:184121
https://doi.org/10.1038/s41380-024-02631-4
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_23EAC9CDB4DD2
https://serval.unil.ch/notice/serval:BIB_23EAC9CDB4DD
https://serval.unil.ch/resource/serval:BIB_23EAC9CDB4DD.P001/REF.pdf
https://boris.unibe.ch/197694/

Analysis of clinical studies on clozapine from 2012-2022

Autoren: Freibüchler, Anton Seifert, Roland

Quelle: Naunyn Schmiedebergs Arch Pharmacol

Schlagwörter: Schizophrenia, Treatment-Resistant/drug therapy [MeSH], Antipsychotic Agents/therapeutic use [MeSH], Humans [MeSH], Clozapine/adverse effects [MeSH], Clozapine, Schizophrenia/drug therapy [MeSH], Schizophrenia, Research, Antipsychotic Agents/pharmacology [MeSH], Schizoaffective disorder, Clozapine/pharmacology [MeSH], Clozapine/pharmacokinetics [MeSH], Clozapine/therapeutic use [MeSH], 03 medical and health sciences, 0302 clinical medicine, Humans, Schizophrenia, Treatment-Resistant, Antipsychotic Agents, 3. Good health

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38918233
https://repository.publisso.de/resource/frl:6501320

Lithium, the gold standard drug for bipolar disorder: analysis of current clinical studies

Autoren: Airainer, Magdalena Seifert, Roland

Quelle: Naunyn Schmiedebergs Arch Pharmacol

Schlagwörter: 03 medical and health sciences, Bipolar Disorder, Treatment Outcome, 0302 clinical medicine, Antimanic Agents, Research, Lithium Compounds, Humans, Drug Therapy, Combination, Lithium, Antimanic Agents/therapeutic use [MeSH], Antipsychotic Agents/adverse effects [MeSH], Antipsychotic Agents/therapeutic use [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Bipolar Disorder/drug therapy [MeSH], Mania, Antimanic Agents/adverse effects [MeSH], Depression, Bipolar disease, Drug Therapy, Combination [MeSH], Lithium Compounds/adverse effects [MeSH], Lithium Compounds/therapeutic use [MeSH], Antipsychotic Agents, 3. Good health

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38916833
https://repository.publisso.de/resource/frl:6516539

The European psychiatric association (EPA) – early career psychiatrists committee survey on trainees’ and early-career psychiatrists’ attitudes towards therapeutic drug monitoring (TDM) use and utility during antipsychotic treatment

Autoren: Schoretsanitis, Georgios Correll, Christoph U Agorastos, Agorastos et al.

Weitere Verfasser: Schoretsanitis, Georgios Correll, Christoph U Agorastos, Agorastos et al.

Quelle: The World Journal of Biological Psychiatry. 25:342-351

Schlagwörter: Male, Adult, Early career psychiatrists (ECPs)therapeutic drug monitoring (TDM)personalised medicinepsychopharmacologyschizophrenia, Attitude of Health Personnel, 610 Medicine & health, Practice Patterns, Physicians'/statistics & numerical data, 2738 Psychiatry and Mental Health, Medical, Surveys and Questionnaires, Humans, Early career psychiatrists (ECPs), Practice Patterns, Physicians', Societies, Medical, psychopharmacology, Psychiatry, therapeutic drug monitoring (TDM), personalised medicine, Internship and Residency, 3. Good health, schizophrenia, Europe, Cross-Sectional Studies, 10054 Clinic for Psychiatry, Psychotherapy, and Psychosomatics, Female, Drug Monitoring, Societies, 2803 Biological Psychiatry, Psychiatrists, Antipsychotic Agents/therapeutic use, Antipsychotic Agents

Dateibeschreibung: Schoretsanitis_2024_WFSBP.pdf - application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38905131
https://www.tandfonline.com/doi/full/10.1080/15622975.2024.2367138
https://doi.org/10.1080/15622975.2024.2367138
https://www.zora.uzh.ch/id/eprint/268760/
https://doi.org/10.5167/uzh-268760

Therapeutic Drug Monitoring of Olanzapine: Effects of Clinical Factors on Plasma Concentrations in Psychiatric Patients

Autoren: Nicolas Ansermot Harish Vathanarasa Setareh Ranjbar et al.

Quelle: Ther Drug Monit
Therapeutic drug monitoring, vol. 46, no. 6, pp. 828-836

Schlagwörter: 03 medical and health sciences, 0302 clinical medicine, Humans, Olanzapine/blood, Male, Female, Drug Monitoring/methods, Middle Aged, Adult, Antipsychotic Agents/blood, Antipsychotic Agents/therapeutic use, Antipsychotic Agents/pharmacokinetics, Mental Disorders/drug therapy, Mental Disorders/blood, Benzodiazepines/blood, Benzodiazepines/therapeutic use, Benzodiazepines/pharmacokinetics, Cohort Studies, Aged, Smoking/blood, Sex Factors, Body Weight, Young Adult, Age Factors, clinical factors, olanzapine, plasma concentrations, therapeutic drug monitoring, Original Article, 3. Good health

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38833576
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_4F77D255DA0E5
https://serval.unil.ch/notice/serval:BIB_4F77D255DA0E
https://serval.unil.ch/resource/serval:BIB_4F77D255DA0E.P002/REF.pdf

Dopamine D2/3R availability after discontinuation of antipsychotic treatment: a [11C]raclopride PET study in remitted first-episode psychosis patients: a [11C]raclopride PET study in remitted first-episode psychosis patients.

Autoren: Franciska de Beer Erik de Vries Ben Wijnen et al.

Quelle: Psychological Medicine. 55

Schlagwörter: Male, Adult, positron emission tomography, antipsychotic discontinuation, First-episode psychosis, Dopamine D3/metabolism, antipsychotic medication, Young Adult, Dopamine D2 Receptor Antagonists, psychotic relapse, Raclopride, Recurrence, Corpus Striatum/metabolism, Positron-Emission Tomography, Case-Control Studies, Receptors, Humans, Female, Dopamine D2/metabolism, dopamine, Psychotic Disorders/drug therapy, Antipsychotic Agents/therapeutic use

Zugangs-URL: https://research.rug.nl/en/publications/4d50a15f-b7d5-4a85-87e5-858e73fbd9af
https://hdl.handle.net/11370/4d50a15f-b7d5-4a85-87e5-858e73fbd9af
https://doi.org/10.1017/S003329172510161X
https://pure.amsterdamumc.nl/en/publications/930232ab-3d7b-435a-afa6-bbf4e4b9228e
https://doi.org/10.1017/S003329172510161X

Video consultation and treatment in the community smoking cessation therapy success rates in patients with mental illness: a randomized controlled trial: a randomized controlled trial

Autoren: Kaasgaard, Didde Marie Sørensen, Mette Knudsgaard Christiansen, Rikke Bleeg et al.

Quelle: Nordic Journal of Psychiatry. 78:272-280

Schlagwörter: Male, Adult, Smoking Cessation/methods, Smoking cessation, Weight Gain, 03 medical and health sciences, Schizophrenia/therapy, 0302 clinical medicine, severe mental illness, Humans, Mood Disorders, Middle Aged, Tobacco Use Cessation Devices, 3. Good health, Treatment Outcome, randomized controlled trial, Schizophrenia, Videoconferencing, video conferencing, Smoking Cessation, Female, Mood Disorders/therapy, physical health, Antipsychotic Agents/therapeutic use, Antipsychotic Agents, Follow-Up Studies

Dateibeschreibung: text

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38385357
https://portal.findresearcher.sdu.dk/da/publications/3289077b-4229-4863-b584-bb5e9f9e3d85
https://doi.org/10.1080/08039488.2024.2318305

The association between clinical, sociodemographic, familial, and environmental factors and treatment resistance in schizophrenia: A machine-learning-based approach: A machine-learning-based approach

Autoren: van Hooijdonk, Carmen F. M. van der Pluijm, Marieke de Vries, Bart M. et al.

Quelle: van Hooijdonk, C F M, van der Pluijm, M, de Vries, B M, Cysouw, M, Alizadeh, B Z, Simons, C J P, van Amelsvoort, T A M J, Booij, J, Selten, J-P, de Haan, L, Schirmbeck, F & van de Giessen, E 2023, 'The association between clinical, sociodemographic, familial, and environmental factors and treatment resistance in schizophrenia : A machine-learning-based approach', Schizophrenia Research, vol. 262, pp. 132-141. https://doi.org/10.1016/j.schres.2023.10.030

Schlagwörter: Psychotic disorders, Precision medicine, Treatment response, Clozapine/therapeutic use, 3. Good health, Schizophrenia/drug therapy, Psychotic Disorders, Schizophrenia, Humans, Prospective Studies, Psychotic Disorders/drug therapy, Prediction, Clozapine, Antipsychotic Agents/therapeutic use, Antipsychotic Agents

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37950936
https://research.rug.nl/en/publications/a6ff14da-f6d8-435c-af18-50e7541e4549
https://doi.org/10.1016/j.schres.2023.10.030
https://hdl.handle.net/11370/a6ff14da-f6d8-435c-af18-50e7541e4549
https://cris.maastrichtuniversity.nl/en/publications/8d83cea8-1cf4-44d4-93b4-b5fab74b6088
https://doi.org/10.1016/j.schres.2023.10.030
https://research.vumc.nl/en/publications/a6b3a5a4-74aa-4bfa-a45e-efcb561f431e
https://pure.amsterdamumc.nl/en/publications/735e1e3f-94b8-44b2-891f-adbef323f31c
https://doi.org/10.1016/j.schres.2023.10.030

Polypharmacy in antipsychotic pharmacological treatment among patients with dual diagnosis in Denmark

Autoren: Lei Blandin Jobe Solvej Mårtensson Signe Wegmann Düring

Quelle: Nordic Journal of Psychiatry. 78:112-119

Schlagwörter: Dual (Psychiatry), Adult, Adolescent, Substance-Related Disorders, Denmark, Substance-Related Disorders/drug therapy, Middle Aged, Denmark/epidemiology, 3. Good health, Hospitalization, Young Adult, Diagnosis, Dual (Psychiatry), Diagnosis, Polypharmacy, Humans, Antipsychotic Agents/therapeutic use, Antipsychotic Agents

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37938028

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults:LQD a pragmatic randomised controlled trial

Quelle: 2025, 'Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults : LQD a pragmatic randomised controlled trial', Health technology assessment (Winchester, England), vol. 29, no. 12, pp. 1-118. https://doi.org/10.3310/YQVF5347

Schlagwörter: Humans, Quetiapine Fumarate/therapeutic use, Cost-Benefit Analysis, Female, Male, Middle Aged, Depressive Disorder, Treatment-Resistant/drug therapy, Adult, Antipsychotic Agents/therapeutic use, Antidepressive Agents/therapeutic use, Drug Therapy, Combination, Quality-Adjusted Life Years, Aged, England, Lithium/therapeutic use

Verfügbarkeit: https://hdl.handle.net/1983/c8db7026-224f-43a2-89a0-4a7f73692846
https://research-information.bris.ac.uk/en/publications/c8db7026-224f-43a2-89a0-4a7f73692846
https://doi.org/10.3310/YQVF5347

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression:a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK

Autoren: Cleare, Anthony J Kerr-Gaffney, Jess Goldsmith, Kimberley et al.

Quelle: Cleare, A J, Kerr-Gaffney, J, Goldsmith, K, Zenasni, Z, Yaziji, N, Jin, H, Colasanti, A, Geddes, J R, Kessler, D, McAllister-Williams, R H, Young, A H, Barrera, A, Marwood, L & Taylor, R W & Tee, H 2025, 'Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression : a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK', Lancet Psychiatry, vol. 12, no. 4, pp. 276-288. https://doi.org/10.1016/S2215-0366(25)00028-8

Schlagwörter: Humans, Quetiapine Fumarate/therapeutic use, Depressive Disorder, Treatment-Resistant/drug therapy, Cost-Benefit Analysis, Male, Female, Adult, Middle Aged, Drug Therapy, Combination/economics, Antipsychotic Agents/therapeutic use, Antidepressive Agents/therapeutic use, United Kingdom, Treatment Outcome, Lithium/therapeutic use

Verfügbarkeit: https://hdl.handle.net/1983/bebc6e60-d102-4ad8-8c00-49ae4f93e153
https://research-information.bris.ac.uk/en/publications/bebc6e60-d102-4ad8-8c00-49ae4f93e153
https://doi.org/10.1016/S2215-0366(25)00028-8

Drug Treatment of Borderline Personality Disorder Symptomatic Dimensions: Evidence­ ‑Based Recommendations ; Tratamento Farmacológico das Dimensões Sintomáticas da Perturbação de Personalidade Borderline: Recomendações Baseadas na Evidência

Autoren: Siopa, Carlos Silva, Francisco Souto Braz, Inês

Quelle: Revista Portuguesa de Psiquiatria e Saúde Mental; Ahead of Print ; 2184-5417 ; 2184-5522

Schlagwörter: Antidepressive Agents/therapeutic use, Antipsychotic Agents/therapeutic use, Borderline Personality Disorder/drug therapy, Psychotherapy, Antidepressivos/uso terapêutico, Antipsicóticos/uso terapêutico, Perturbação de Personalidade Borderline/tratamento farmacológico, Psicoterapia

Dateibeschreibung: application/pdf

Relation: https://www.revistapsiquiatria.pt/index.php/sppsm/article/view/542/171; https://www.revistapsiquiatria.pt/index.php/sppsm/article/view/542

Verfügbarkeit: https://www.revistapsiquiatria.pt/index.php/sppsm/article/view/542
https://doi.org/10.51338/rppsm.542

Association of Psychotropic Prescriptions With Non‐Registered Indications and the Risk of Mortality in Older Adults: A Danish Nationwide Cohort Study

Autoren: Kazi Ishtiak‐Ahmed Christina Jensen‐Dahm Kaj Sparle Christensen et al.

Quelle: Ishtiak-Ahmed, K, Jensen-Dahm, C, Christensen, K S, Waldemar, G & Gasse, C 2024, 'Association of Psychotropic Prescriptions With Non-Registered Indications and the Risk of Mortality in Older Adults : A Danish Nationwide Cohort Study', International Journal of Geriatric Psychiatry, vol. 39, no. 11, e70014. https://doi.org/10.1002/gps.70014

Schlagwörter: Male, Drug Prescriptions/statistics & numerical data, Denmark, Dementia/drug therapy, Antidepressive Agents/therapeutic use, Drug Prescriptions, Psychotropic Drugs/therapeutic use, Cohort Studies, Benzodiazepines, Benzodiazepines/therapeutic use, Humans, Registries, Mortality, benzodiazepines, Aged, Aged, 80 and over, Psychotropic Drugs, Mental Disorders, off-label medication use, Off-Label Use, Mortality/trends, Mental Disorders/drug therapy, Off-Label Use/statistics & numerical data, Denmark/epidemiology, Antidepressive Agents, antipsychotics, antidepressants, Female, Dementia, Antipsychotic Agents/therapeutic use, dementia, Antipsychotic Agents

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39549021

Pharmacotherapy for behavioural manifestations in frontotemporal dementia: An expert consensus from the European Reference Network for Rare Neurological Diseases (ERN‐RND)

Autoren: Casper Wittebrood Marina Boban Annchiara Cagnin et al.

Quelle: Eur J Neurol
European journal of neurology 31(12), e16446 (2024). doi:10.1111/ene.16446

Schlagwörter: SYMPTOMS, Consensus, ALS and frontotemporal dementia, expert testimony, VARIANT, Clinical Neurology, DIAGNOSIS, frontotemporal dementia, drug effects [Aggression], Rare Diseases, drug therapy [Frontotemporal Dementia], MANAGEMENT, Humans, neurodegenerative diseases, LOBAR DEGENERATION, ddc:610, Frontotemporal Dementia / drug therapy, Science & Technology, Neurology & Neurosurgery, Rare Diseases / drug therapy, drug therapy [Rare Diseases], Neurosciences, 3202 Clinical sciences, 1103 Clinical Sciences, therapeutic use [Selective Serotonin Reuptake Inhibitors], Aggression / drug effects, OPEN-LABEL, drug effects [Impulsive Behavior], drug therapy, neurobehavioural manifestations, Europe, Aggression, MEMANTINE, Impulsive Behavior / drug effects, ARIPIPRAZOLE, therapeutic use [Antipsychotic Agents], Frontotemporal Dementia, 3209 Neurosciences, Impulsive Behavior, DONEPEZIL, Antipsychotic Agents / therapeutic use, Neurosciences & Neurology, Selective Serotonin Reuptake Inhibitors / therapeutic use, 1109 Neurosciences, Life Sciences & Biomedicine, Selective Serotonin Reuptake Inhibitors, Antipsychotic Agents

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39447217
https://lirias.kuleuven.be/handle/20.500.12942/757217
https://doi.org/10.1111/ene.16446
https://hdl.handle.net/11577/3543325
https://doi.org/10.1111/ene.16446
https://hdl.handle.net/11585/1008151
https://onlinelibrary.wiley.com/doi/10.1111/ene.16446
https://doi.org/10.1111/ene.16446
https://urn.nsk.hr/urn:nbn:hr:105:493983
https://doi.org/10.1111/ene.16446

Promising translatable pharmacological interventions for body weight management in individuals with severe mental illness – a narrative review

Autoren: Riddhita De Femin Prasad Nicolette Stogios et al.

Quelle: Expert Opinion on Pharmacotherapy. 24:1823-1832

Schlagwörter: 2. Zero hunger, Obesity/drug therapy, Mental Disorders, Weight Gain, Mental Disorders/drug therapy, 3. Good health, Type 2/drug therapy, Diabetes Mellitus, Type 2, Weight Loss, Diabetes Mellitus, Quality of Life, Humans, Obesity, Antipsychotic Agents/therapeutic use, Antipsychotic Agents

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37653675

Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK: a retrospective cohort study in Wales, UK

Autoren: Schnier, Christian McCarthy, Aoife Morales, Daniel R. et al.

Quelle: Schnier, C 2023, ' Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic : a retrospective cohort study in Wales, UK ', The Lancet Healthy Longevity, vol. 4, no. 8, pp. e421-e430 . https://doi.org/10.1016/S2666-7568(23)00105-8

Schlagwörter: Male, Myocardial Infarction/drug therapy, Myocardial Infarction, Dementia/drug therapy, Drug Prescriptions, name=Psychiatry and Mental health, Humans, Pandemics, Wales/epidemiology, Aged, Retrospective Studies, Wales, SARS-CoV-2, name=Geriatrics and Gerontology, name=Health(social science), COVID-19, Middle Aged, 3. Good health, Stroke, name=Family Practice, Female, Dementia, Stroke/drug therapy, Antipsychotic Agents/therapeutic use, Antipsychotic Agents

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37543047
https://cronfa.swan.ac.uk/Record/cronfa64020/Download/64020__28534__0023d409c42d4514bc86bfc6c7688227.pdf
https://cronfa.swan.ac.uk/Record/cronfa62717/Download/62717__28891__d05c720ee94645438d1e5098c74f5878.pdf
https://www.pure.ed.ac.uk/ws/files/371031743/PIIS2666756823001058.pdf
https://hdl.handle.net/20.500.11820/7ad0b4fb-d47f-4759-a9ea-a26eaf5c7002

Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review

Autoren: Baumann, Pierre Bauknecht, Philipp Kuzin, Maxim et al.

Weitere Verfasser: Baumann, Pierre Bauknecht, Philipp Kuzin, Maxim et al.

Quelle: International journal of psychiatry in clinical practice, vol. 27, no. 4, pp. 367-384

Schlagwörter: brexpiprazole, cariprazine, Dopamine, Aripiprazole, 610 Medicine & health, switch, 3. Good health, dopamine receptor agonists, schizophrenia spectrum disease, 2738 Psychiatry and Mental Health, Psychiatry and Mental health, antipsychotics, aripiprazole, Humans, Antipsychotic Agents/therapeutic use, Schizophrenia/drug therapy, Dopamine Agonists/therapeutic use, Dopamine/therapeutic use, Partial D2-dopamine receptor agonists, 10054 Clinic for Psychiatry, Psychotherapy, and Psychosomatics, Dopamine Agonists, Schizophrenia, Partial D2, Antipsychotic Agents

Dateibeschreibung: application/pdf; Switching_antipsychotics_to_partial_dopamine_D2_agonists_in_individuals_affected_by_schizophrenia__a_narrative_review.pdf - application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37428441
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_58F657E999219
https://serval.unil.ch/resource/serval:BIB_58F657E99921.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_58F657E99921
https://www.zora.uzh.ch/id/eprint/256915/
https://doi.org/10.5167/uzh-256915

Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium

Autoren: Smart, Sophie E Agbedjro, Deborah Pardiñas, Antonio F et al.

Weitere Verfasser: Smart, Sophie E Agbedjro, Deborah Pardiñas, Antonio F et al.

Quelle: Schizophr Res
RISalud-ANDALUCIA. Repositorio Institucional de Salud de Andalucía
instname
Schizophrenia research, vol. 250, pp. 1-9
Smart, S E, Agbedjro, D, Pardiñas, A F, Ajnakina, O, Alameda, L, Andreassen, O A, Barnes, T R E, Berardi, D, Camporesi, S, Cleusix, M, Conus, P, Crespo-Facorro, B, D'Andrea, G, Demjaha, A, Di Forti, M, Do, K, Doody, G, Eap, C B, Ferchiou, A, Guidi, L, Homman, L, Jenni, R, Joyce, E, Kassoumeri, L, Lastrina, O, Melle, I, Morgan, C, O'Neill, F A, Pignon, B, Restellini, R, Richard, J-R, Simonsen, C, Španiel, F, Szöke, A, Tarricone, I, Tortelli, A, Üçok, A, Vázquez-Bourgon, J, Murray, R M, Walters, J T R, Stahl, D & MacCabe, J H 2022, 'Clinical predictors of antipsychotic treatment resistance: Development and internal validation of a prognostic prediction model by the STRATA-G consortium', Schizophrenia research, vol. 250, pp. 1-9. https://doi.org/10.1016/j.schres.2022.09.009

Schlagwörter: Psychotic Disorders / diagnosis, First episode psychosis, Trastornos psicóticos, Educación, Terapéutica, Riesgo, Psykiatri, Article, 03 medical and health sciences, 0302 clinical medicine, Prospective longitudinal cohort, Machine learning, Humans, name=SDG 3 - Good Health and Well-being, Prospective Studies, Optimismo, Psychiatry, Antipsychotic Agents/therapeutic use, Prognosis, Psychotic Disorders/diagnosis, Educational Status, Prediction modelling, Stratification, Treatment resistant schizophrenia, Sensibilidad y especificidad, 3. Good health, Psychotic Disorders, Pacientes, Antipsychotic Agents / therapeutic use, Antipsicóticos, Antipsychotic Agents

Dateibeschreibung: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36242784
http://hdl.handle.net/10668/22510
https://archive-ouverte.unige.ch/unige:184311
https://doi.org/10.1016/j.schres.2022.09.009
https://serval.unil.ch/resource/serval:BIB_FD83206AB9D6.P001/REF.pdf
https://serval.unil.ch/notice/serval:BIB_FD83206AB9D6
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_FD83206AB9D69
https://pure.qub.ac.uk/en/publications/942250fb-fcc9-4c1f-8920-45e259d6f211
https://hdl.handle.net/10668/22510
https://www.sciencedirect.com/science/article/pii/S0920996422003425
https://doi.org/10.1016/j.schres.2022.09.009
https://hdl.handle.net/11585/917875
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-189357
https://discovery-pp.ucl.ac.uk/id/eprint/10157682/